Akari Therapeutics Plc
Close on Oct 19, 2026
- Market cap
- $1.42T
- P/E (TTM)
- –
- Dividend yield
- –
About Akari Therapeutics
Pharmaceutical Preparations, SIC 2834
The provided text does not contain factual descriptions or narrative details concerning what the company does, its specific products, operational segments, or customer base. The text consists entirely of XBRL metadata tags, SEC filing identifier codes, dates, and accounting taxonomy members relating to shares, notes, and warrants.
Similarly, no information is provided regarding the company's operating scale, store count, geographical presence, or headquarters location. While ticker symbols and entity members such as AKTX and Peak Bio appear within the raw data strings, the excerpt contains no descriptive prose from which a business profile or operational facts can be derived.
Summary of the business section of Akari Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Akari Therapeutics Plc
- Headquarters
- Tampa, FL
- Address
- 401 East Jackson Street, Suite 3300 33602
- Phone
- (929) 274-7510
- Employees
- 6, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- X0
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., New York, New York
Stock & identifiers
- Ticker
- AKTX
- Exchange
- Nasdaq
- IPO date
- Jan 31, 2014
- Shares outstanding
- 155.76B, Aug 13, 2026
- Public float
- $15.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-40 reverse, Mar 31, 2026; 1-for-20 reverse, Aug 17, 2023; 13-for-1, Nov 23, 2015; 1-for-10 reverse, Sep 17, 2015
- SEC CIK
- 1541157
- CUSIP
- 00972G405
- ISIN
- US00972G4055
- LEI
- 2138001XURASAU3MEB68
- EIN
- 98-1034922
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Abizer Gaslightwala | CEO, Director | 298,574 |
| Kameel D. Farag | Interim CFO | 23,309 |
| Torsten Hombeck | CFO | 200 |
| Samir Rashmikant Patel | Director | 101,807 |
| James R. Neal | Director | 36,271 |
| Hoyoung Huh | Director | 4,805,311 |
| Sandip I. Patel | Director | 556,749 |
| Raymond Prudo-Chlebosz | Director | 2,904,728 |
| Robert B. Bazemore | Director | 44,642 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Peo1 | $1.66M | $485.93K | $369.70K | $3 | – |
| FY2025 Peo2 | $324.99K | $324.99K | $369.70K | $3 | – |
| FY2024 Peo1 | $435.77K | $435.77K | $436.67K | $4 | – |
| FY2024 Peo2 | $435.77K | $435.77K | $436.67K | $4 | – |
| FY2023 Peo2 | $1.56M | $979.80K | $222.59K | $10 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of March 1, 2026, we had 6 employees, 5 of which are full-time, including our Chief Executive Officer, Abizer Gaslightwala, our Executive”
Corporate history
Events identified from SEC filings